Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of May 2022. The report, dated May 10, 2022, serves as a vehicle to distribute a press release (Exhibit 99.1) to U.S. investors. The company is headquartered in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The provided filing text contains only the cover page and exhibit index for the Form 6-K. It does not include the content of the press release or any financial statements. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, liquidity, or other key financial metrics.
Material Changes
No material changes versus the prior comparable period can be identified from the provided text, as the document lacks the underlying data or narrative from the referenced press release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These elements would be contained within the attached press release (Exhibit 99.1), which is not included in the input content.
Key Facts for Investor Verification
- The filing is a procedural Form 6-K referencing a press release dated May 10, 2022, rather than a standalone financial report.
- Specific financial results and operational updates are not present in the provided text and must be sourced from the full press release.
- The report is signed by Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer.